Anticancer Effects of a New Aminosugar-conjugated Platinum Complex Agent Against Cisplatin-resistant Gastric Cancer

NORIYUKI HAYASHI1, HIROMI KATAOKA1, SHIGENOBU YANO2,3, JUN-ICHI KIKUCHI2, MAMORU TANAKA1, HIROTADA NISHIE1, YUMA KINOSHITA4, MIKI HATANO5, AKIHIRO NOMOTO4, AKIYA OGAWA4, MASARIO INOUE3, TSUTOMU MIZOSHITA1, TAKAYA SHIMURA1, YOSHINORI MORI1, EJII KUBOTA1, SATOSHI TANIDA1 and TAKASHI JOH1

1Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;
2Graduate School of Materials Science, Nara Institute of Science and Technology, Nara, Japan;
3Office of Society-Academia Collaboration for Innovation, Kyoto University, Kyoto, Japan;
4Department of Applied Chemistry, Graduate School of Engineering, Osaka Prefecture University, Osaka, Japan;
5Department of Biochemistry, Osaka Medical Centre for Cancer and Cardiovascular Diseases, Osaka, Japan

Abstract. Background/Aim: Resistance against cisplatin is a problem for the success of gastric cancer chemotherapy. Herein, we evaluated the antitumor effect of a new aminosugar-conjugated, mono-functional platinum complex (Pt-Oqn), which forms a single covalent bond with DNA. Materials and Methods: We compared the cytotoxicity of Pt-Oqn to that of cisplatin (CDDP), oxaliplatin (L-OHP) and carboplatin (CBDCA). We also compared Pt-Oqn and cisplatin for DNA double-strand breaks based on phosphorylated histone H2AX levels in cancer cells and antitumor effects in xenograft models. Results: The resistance factor (RF) for Pt-Oqn was low among the four drugs, indicating the potential of Pt-Oqn for overcoming CDDP-induced resistance. In MKN45-R cells, γ-H2AX protein increased following treatment with Pt-Oqn, but not with cisplatin. Finally, Pt-Oqn, but not cisplatin, showed significant antitumor effects in MKN45-R xenografts. Conclusion: This new aminosugar-conjugated platinum complex is a promising candidate agent for overcoming the drug resistance of cisplatin-resistant stomach cancer.

The platinum drug cisplatin (CDDP) is used in cancer chemotherapy to treat a variety of tumors (1). Unfortunately, the effectiveness of CDDP treatment is limited by side-effects, such as nephrotoxicity, neurotoxicity, ototoxicity and severe emesis, as well as by the acquisition of drug resistance to cancer chemotherapy, especially in gastric cancer (2). New agents effective against cisplatin-resistant tumors are, thus, a priority in cancer treatment (3) and various platinum complexes have been studied in recent years to overcome these problems (4-7).

CDDP typically binds to and damages genomic DNA through the formation bifunctional intra-strand lesions that inhibit transcription and induce cell death by apoptosis. This mechanism inherently brings with it the above-described side-effects and tolerance; thus, new platinum drugs would ideally act via different cytotoxic mechanisms from that of CDDP (8).

Recently, numerous monofunctional platinum complexes were developed as novel non-classical anticancer agents (8-10). These drugs act by forming a single covalent bond with DNA to induce cancer cell death. In this study, we synthesized a new such platinum complex (Pt-Oqn=[chloro[N-(8-hydroxyquinoline-2-ylmethylidene)-β-D-glucosamine] platinum(II)]) as a novel monofunctional platinum anticancer agent and evaluated its cytotoxicity and ability to induce DNA double-strand breaks in CDDP-sensitive and -resistant gastric cancer cell lines in vitro and in vivo compared to CDDP, carboplatin (CBDCA) and oxaliplatin (L-OHP).

Materials and Methods

Drugs. CDDP and CBDA were purchased from Bristol-Myers Co. (Tokyo, Japan). L-OHP was purchased from Yakult Co. (Tokyo, Japan). Pt-Oqn, the newly obtained Schiff base (L) formed from the reaction between D(+)-glucosamine and 8-hydroxyquinoline-2-
carbdehyde reacted with Pt(DMSO)2Cl2 to yield Pt-Oqn. HCl·0.5 MeOH. Anal. Calcd for Pt-Oqn·0.5 HCl·0.5 MeOH: C, 33.13; H, 3.29; N, 4.68. Found: C, 32.92; H, 3.24; N, 4.96. ESI-MS m/z: [M+Na]+ calcd for C16H17ClN2NaO6Pt: 586.03206, found: 586.03278.

Measurements. 1H and 13C-NMR spectra were recorded on JEOL ECX 400 or ECS 400 (400 MHz) spectrometers (JEOL Ltd., Tokyo, Japan). Elemental analysis was carried out on a YANACO MT-5 (Yanaco Analytical Instruments Inc., Kyoto, Japan) and ESI-mass spectra were measured on a JEOL JMS-T100LC (JEOL Ltd.).

Crystallography. Crystallographic data for Pt-Oqn·0.5 HCl·0.5 MeOH was deposited with the Cambridge Crystallographic Data Center (CCDC 1454737): 12 Union Road, Cambridge CB21EZ, UK (Fax: +44 1223363033, e-mail: deposit@ccdc.cam.ac.uk).

Cell culture. The human gastric cancer cell lines MKN28 (Japanese Collection of Research Bioresources, Osaka, Japan) and MKN45 (RIKEN BRC, Ibaragi, Japan) were cultured in RPMI1640 (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum. Cell authentication (STR profile) was performed for all human cancer cell lines (MKN28 and MKN45) by Japanese Collection of Research Bioresources (JCRB) cell bank on February 25, 2014.

Establishment of CDDP-resistant sublines from MKN28 and MKN45. CDDP-resistant MKN28 (MKN28-R) and MKN45 (MKN45-R) cell lines were established by continuous exposure to CDDP starting at 0.5 μmol/l and increasing in a stepwise manner to 10 μmol/l for more than 5 months. Experiments with these sublines were performed after maintenance in CDDP-free medium for 2-3 weeks.

In vitro cytotoxicity. Cell viability was measured by using a WST-8 cell proliferation assay (Dojindo, Kumamoto, Japan). Gastric cancer cells were seeded into 96-well culture plates at 5×103 cells/100 μl/well and incubated overnight. Cells were treated for 48 h with graded concentrations of CDDP, Pt-Oqn, L-OHP or CBDCA. To determine cell survival, cells were incubated with cell counting kit-8 solution for 4 h and absorption at 450 nm was measured with a microplate reader (SPECTRA MAX340; Molecular Devices, Sunnyvale, CA, USA). Cell viability was expressed as a percentage of treated cells vs. untreated control cells. The half maximal (50%) inhibitory concentration (IC50) was calculated. Resistance factor (RF) is defined as the relative ratio of IC50 values in both cell lines (MKN28-R/MKN28 or MKN45-R/MKN45).

Assessment of DNA double-strand breaks. Gastric cancer cells were seeded and incubated overnight. Cells were treated for 48 h with CDDP (25, 100, 400 μmol/l) and Pt-Oqn (25, 100, 400 μmol/l). Western blotting was performed by using anti-γH2AX (1:2,000; Bethyl Laboratories, Inc., TX, USA).

Animals and tumor models. Pathogen-free female nude mice (BALB/c Slc-nu/nu) aged 4 weeks and weighing 20-25 g were obtained from Japan SLC (Kyoto, Japan). Animals were allowed to acclimatize for 2 weeks in the animal facility before any interventions were initiated. Xenograft tumor models were established by implanting 1×106 gastric cancer cells (MKN45, MKN45-R) subcutaneously under their right flank. The procedures and experiments were approved by Nagoya City University Center for Experimental Animal Science and mice were cared for according to the guidelines of the Nagoya City University for Animal Experiments.

In vivo treatment. When transplanted tumors grew to approximately 100 mm3, mice were given intraperitoneal injections of CDDP and Pt-Oqn at a dose of 40 μmol/kg on day 1 and 8. Tumor growth was monitored by measuring tumor volume with Vernier calipers and calculated using the following formula: (length × width × width/2). Relative tumor growth was assessed by comparing tumor volume with that measured on day 1. The Pt-Oqn, CDDP and control groups consisted of 6, 5 and 5 mice, respectively. Results were analyzed by multiple testing (Tukey-Kramer method) between groups.

Statistical analysis. The statistical significance of differences was determined using Student’s t-test or the Tukey–Kramer method. Differences were considered statistically significant at p<0.05. Data are expressed as means±SE.

Results

Structure of [Pt-Oqn]. A platinum(II) is coordinated in a square planar geometry composed of a tridentate Schiff base anion (L–) and a chloride anion (Figure 1). The glucosamine ring takes the usual β-1,4C1 conformation as shown in the 1H-NMR study on Pt-Oqn in DMF-d7/D2O (SI).

Pt-Oqn revealed minimal resistance in CDDP-resistant gastric cancer cells. First, we evaluated the cytotoxicity of CDDP, Pt-Oqn, L-OHP and CBDCA against gastric cancer cells. As shown in Table I, Pt-Oqn exhibited the highest cytotoxicity among the four drugs in MKN28-R cells, while, in the MKN45-R cell line, Pt-Oqn exhibited higher cytotoxicity than CDDP and CBDCA. The RF (MKN28-R/MKN28) of Pt-Oqn was also the lowest among the four drugs, indicating that Pt-Oqn most successfully overcame any cross-resistance of CDDP in the MKN28 cells. For RF (MKN45-R/MKN45), Pt-Oqn was 2nd-lowest among the four drugs (CBDCA: 0.89, Pt-Oqn: 0.92) with a big difference over the RFs of CDDP (5.31) and L-OHP (6.64). These findings together suggested the strong potential of Pt-Oqn for overcoming CDDP-induced resistance in gastric cancer cell lines.

Pt-Oqn induced DNA double-strand breaks in CDDP-resistant gastric cancer cells. Phosphorylated histone H2AX (γ-H2AX) was used herein as a marker of DNA damage and, in MKN45 cells treated with either 400 μmol/l CDDP or Pt-Oqn, γ-H2AX protein levels were increased comparably. On the other hand, in MKN45-R, γ-H2AX protein levels were increased by Pt-Oqn, but not CDDP, at 400 μmol/l (Figure 2). These results indicate that Pt-Oqn, but not CDDP, induced DNA double-strand breaks in CDDP-resistant gastric cancer cells.

Pt-Oqn significantly suppressed CDDP-resistant gastric cancer cell growth. Finally, we examined the antitumor effects of CDDP and Pt-Oqn on xenograft tumor models. As shown...
in Figure 3, CDDP and Pt-Oqn significantly suppressed tumor growth compared to an untreated control in MKN45 xenografts. On the other hand, only Pt-Oqn significantly suppressed tumor growth compared to controls in the MKN45-R xenografts. None of the therapies had any obvious side-effects, such as diarrhea or weight loss.

Discussion

CDDP is the prototype member of a group of platinum-based antineoplastic agents that also includes CBDCA (11), with L-OHP a new diaminocyclohexane-platinum analogue (12). All of these agents typically form bifunctional intrastrand lesions in cancer cells that bind to and damage genomic double-stranded DNA, thereby inhibiting DNA transcription and blocking the cell cycle to ultimately induce cell death (4).

On the other hand, the recently developed Pt-Oqn is a monofunctional platinum-based complex that tends to form 1,4-GG rather than the 1,2-GG intra-strand crosslinks formed by CDDP (13). As shown in Table I, Pt-Oqn synthesized in this study sustained its cytotoxicity against CDDP-resistant MNK28 and MKN45 cells, while L-OHP and CBDCA had no such effect. We speculate that the superior efficacy of Pt-Oqn against the drug-resistant cancer cell lines lies in the different mechanisms of DNA interaction between monofunctional Pt-Oqn and bifunctional CDDP, CBDCA and L-OHP. Indeed, studies into the acquisition of CDDP resistance by cancer cells, decreased CDDP accumulation, increased CDDP inactivation, whereas abnormalities in apoptotic signaling have proposed several different mechanisms (14, 15). Abnormal expression of the adenosine triphosphate (ATP)-binding cassette (ABC) superfamily of transport proteins, multidrug resistance gene-1 (MDR-1) and multidrug resistance-associated proteins (MRPs) have been associated with CDDP resistance (16, 17). In addition, our previous study showed ABCB1 and CDKN2A gene up-regulation in the CDDP-resistant gastric cell line MKN45 (18). ABCB1 gene is the most extensively studied ABC superfamily transporter (19), being implicated in MDR involving CDDP accumulation due to active efflux of drugs (20, 21). CDKN2A might also

Table 1. In vitro cytotoxicity assay in cisplatin (CDDP)-sensitive and resistant gastric and colon cancer cell lines.

<table>
<thead>
<tr>
<th></th>
<th>IC₅₀ (μM)</th>
<th>Resistance factor</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MKN28</td>
<td>MKN28-R</td>
</tr>
<tr>
<td>Pt-Oqn</td>
<td>239.4±12.5</td>
<td>149.8±23.2</td>
</tr>
<tr>
<td>CDDP</td>
<td>186.8±12.8</td>
<td>522.8±59.1</td>
</tr>
<tr>
<td>L-OHP</td>
<td>99.1±13.0</td>
<td>191.7±26.6</td>
</tr>
<tr>
<td>CBDCA</td>
<td>123.1±14.8</td>
<td>422.4±67.4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>IC₅₀ (μM)</th>
<th>Resistance factor</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MKN45</td>
<td>MKN45-R</td>
</tr>
<tr>
<td>Pt-Oqn</td>
<td>187.3±16.1</td>
<td>171.8±33.5</td>
</tr>
<tr>
<td>CDDP</td>
<td>89.9±22.5</td>
<td>477.4±47.4</td>
</tr>
<tr>
<td>L-OHP</td>
<td>13.5±3.6</td>
<td>89.6±9.2</td>
</tr>
<tr>
<td>CBDCA</td>
<td>291.7±826</td>
<td>258.6±20.9</td>
</tr>
</tbody>
</table>

Gastric cancer cells were treated for 48 h with graded concentrations of CDDP, aminosugar-conjugated mono-functional platinum complex (Pt-Oqn), oxaliplatin (L-OHP) or carboplatin (CBDCA). Cell viability was determined by WST-8 assay and expressed by the half maximal inhibitory concentration (IC₅₀). Resistance factor (RF) is defined as the relative ratio of IC₅₀ values in both cell lines (MKN28-R/MKN28 or MKN45-R/MKN45). Data are means of five independent experiments.

Figure 1. Chemical structure of Pt-Oqn. Structures of the complexes used in this study. (a) Molecular structure of Pt-Oqn. (b) Perspective drawing of Pt-Oqn with atomic numbering scheme in the crystal. Selected bond length (Å) and angles (°), Pt1-Cl1 2.3176(17), Pt1-N1 1.1919(6), Pt1-N2 2.036(5), Pt1-O1 2.0664(4), C12-N2 1.487(9), C11-Pt1-N1 176.24(15), C11-Pt1-N2 105.08(15), N1-Pt1-N2 78.4(2), N1-Pt1-O1 82.52(19), C11-Pt1-O1 94.03(12), N2-Pt1-O1 160.89(19).
enhance CDDP resistance by prolonging the cell cycle at the G1-S transition, which allows for DNA repair (22).

Phosphorylation of histone H2AX (γH2AX) is another protein that forms part of the DNA repair complex in response to double-strand breaks, also used as a marker of DNA damage signal by ionizing radiation and several anticancer reagents (23-25). The mechanism of γH2AX formation by CDDP treatment involves replication fork collapse and subsequent DNA double-strand break formation at sites of interstrand crosslinking immediately after DNA double-strand breaks (26, 27). In our study, Pt-Oqn induced DNA double-strand breaks in CDDP-resistant gastric cancer cells that CDDP could not at the same concentrations (Figure 2).

In conclusion, a newly synthesized monofunctional Pt complex that binds to DNA in a monodentate fashion, Pt-Oqn, shows strong activity against CDDP-resistant gastric cancer...
cells and is considered a promising candidate for the next-generation platinum-based antineoplastic agents.

Grant Support

This work was supported by JSPS KAKENHI grant numbers 19350031, 23590923, 25288028, 26288037, 26410056 and 26620154.

Conflicts of Interest

The Authors state that they have no potential conflicts of interest to disclose.

Acknowledgements

The Authors are grateful to Yukimi Ito at Nagoya City University Graduate School of Medical Sciences for technical assistance and the Core Laboratory, Nagoya City University Graduate School of Medical Sciences, for the use of laboratory equipment.

References


Received August 16, 2016
Revised September 3, 2016
Accepted September 6, 2016